Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.50 |
| ▸ | POLRMT | O00411 | 1/20 | 0.41 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.38 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18298281 | 0.94 | TMPRSS2 (0.51) | TMPRSS2POLRMTDNPH1PRKAB2TRPM2 | |
| SCHEMBL17719238 | 0.93 | POLRMT (0.48) | TMPRSS2POLRMT | |
| SCHEMBL24538669 | 0.93 | TMPRSS2 (0.49) | TMPRSS2POLRMTDNPH1PRKAB2TRPM2 | |
| SCHEMBL26326132 | 0.93 | TMPRSS2 (0.49) | TMPRSS2POLRMTDNPH1PRKAB2TRPM2 | |
| SCHEMBL20500115 | 0.93 | TMPRSS2 (0.50) | TMPRSS2POLRMTDNPH1PRKAB2TRPM2 | |
| SCHEMBL25378413 | 0.93 | TMPRSS2 (0.50) | TMPRSS2POLRMTDNPH1PRKAB2TRPM2 | |
| SCHEMBL18697904 | 0.92 | TMPRSS2 (0.43) | TMPRSS2POLRMTDNPH1PRKAB2TRPM2 | |
| Rdv-Tp SCHEMBL24492745 | 0.91 | POLRMT (0.51) | TMPRSS2POLRMTP2RY1 | |
| Rdv-Tp SCHEMBL23278555 | 0.91 | POLRMT (0.51) | TMPRSS2POLRMTP2RY1 | |
| Rdv-Tp SCHEMBL10120881 | 0.91 | POLRMT (0.51) | TMPRSS2POLRMTP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024042050-A1 | USE OF MEK1/2 INHIBITORS TO SYNERGISTICALLY POTENTIATE THE ANTIVIRAL EFFECT OF DIRECT-ACTING ANTI-CORONAVIRUS DRUGS | ATRIVA THERAPEUTICS GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| WO-2023280911-A1 | P38-INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS AND/OR COVID-19 CYTOKINE STORM | Westfälische Wilhelms-Universität Münster (DE) | 2023-01-12 | — | — | WO | claimed |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4605396-A1 | ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Shanghai Curegene Pharmaceutical Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| EP-4588928-A2 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| WO-2025031248-A1 | PEGYLATED PHOSPHORIC ACID PRODRUG AND PREPARATION THEREFOR AND USE THEREOF | 杭州居维叶生物医药有限公司 | 2025-02-13 | — | — | WO | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | UNIV CALIFORNIA (US) | 2025-01-09 | — | — | US | disclosed |
| US-12173029-B2 | Antiviral prodrugs, pharmaceutical formulations, and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4469061-A2 | ANTIVIRAL PRODRUGS, INTERMEDIATE- AND LONG-ACTING FORMULATIONS AND METHODS | The Regents of the University of California (US) | 2024-12-04 | — | — | EP | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885POLRMT 104/4885DNPH1 2260/4885 |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | TMPRSS2 6/4885POLRMT 93/4885DNPH1 3458/4885 |
| US-12173029-B2 | Antiviral prodrugs, pharmaceutical formulations, and methods | MTAP, SARS1, RNGTT | TMPRSS2 181/4885POLRMT 20/4885DNPH1 314/4885 |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | SARS1, ACE2, FURIN | TMPRSS2 8/4885POLRMT 34/4885DNPH1 2403/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | TMPRSS2 21/4885POLRMT 10/4885DNPH1 3519/4885 |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | TMPRSS2 181/4885POLRMT 20/4885DNPH1 314/4885 |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885POLRMT 104/4885DNPH1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.